Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells

The Journal of Investigative Dermatology
Nagisa KunikataTadashi Terui

Abstract

Although melanoma mostly affects the skin, it is notorious for its propensity to easily develop metastasis. Metastatic melanoma is highly resistant to a variety of therapies. We examined the anti-metastatic potential of peritumoral monotherapy against murine cutaneous B16F10 melanoma with synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs. We demonstrated that repeated peritumoral injections of CpG ODN significantly reduced skin tumor size. Peritumoral CpG ODN-treatment of skin tumors prevented the development of pulmonary B16F10 colonies. Adoptive transfer of splenocytes obtained from CpG ODN-treated mice markedly reduced the number of previously established pulmonary colonies in recipient naïve mice. T-lymphocyte depletion studies indicated that the anti-metastatic effect was dependent on both CD4+ and CD8+ T cells. These results suggest that CpG ODN are promising as a preventive and therapeutic anti-metastatic measure against melanoma.

References

Aug 20, 1992·The New England Journal of Medicine·G CocconiP Costa
Apr 6, 1995·Nature·A M KriegD M Klinman
Aug 3, 1994·Journal of the National Cancer Institute·S A RosenbergD E White
Mar 27, 1997·Nature·T SparwasserH Wagner
Dec 31, 1997·The Journal of Experimental Medicine·R S ChuC V Harding
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·G J WeinerA M Krieg
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·G HartmannA M Krieg
Jun 6, 2000·International Immunology·E BanG Riveau
Dec 29, 2000·Nature·H HemmiS Akira

❮ Previous
Next ❯

Citations

Nov 13, 2012·International Immunopharmacology·Liang YangLiying Wang
Jan 25, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kaoru KigasawaKentaro Kogure
Feb 2, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yukari KuramotoMitsuru Hashida
Jan 21, 2015·Nature Reviews. Clinical Oncology·Maya HorowitzShamgar Ben-Eliyahu
Nov 21, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Marion Jurk, Jörg Vollmer
Mar 4, 2018·Pharmaceutical Research·Caixing WuYuhong Xu
Oct 12, 2005·International Journal of Cancer. Journal International Du Cancer·Milan ReinisJan Bubeník
Feb 7, 2007·Cancer Immunology, Immunotherapy : CII·Joanne LysaghtKingston H G Mills
Oct 31, 2019·Biological Reviews of the Cambridge Philosophical Society·Goodwin G Jinesh, Andrew S Brohl
Sep 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·W Nicholas HainingLee M Nadler
May 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Barbara G MolenkampTanja D de Gruijl

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.